Clinical trials: SCHIZOPHRENIA 1 (Disorder)
SCHIZOPHRENIA 1 (Disorder), Schizotypal Disorder
PS-Trauma - Development of Trauma Treatment for Patients With Co-morbid Psychotic Disorders and Traumas
Overview: People with psychotic disorders frequently have a history of traumatic events such as neglect, bullying, or physical and sexual abuse.
- Conditions
- SCHIZOPHRENIA 1 (Disorder), Schizotypal Disorder, Post Traumatic Stress Symptoms
- Trial name
- PS-Trauma (NCT07242586)
- Testing
- Prolonged Exposure, EMDR
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Nikolai Albert
SCHIZOPHRENIA 1 (Disorder), Schizoaffecitve Disorder
A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia
This is a single site clinical trial in which 12 participants with schizophrenia will be randomized to one of three doses of treatment with Cobenfy for 5 weeks.
- Trial name
- NCT07423546
- Testing
- Xanomeline and trospium chloride (KarXT)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia Cognition Autobiographical Memory Cognitive Remediation, SCHIZOPHRENIA 1 (Disorder)
Acceptability and Efficacy of Group Reminiscence Intervention in a Sample of Patients With Schizophrenia
The study aimed to test whether group reminiscence intervention for inpatients with schizophrenia is feasible, acceptable and preliminary effective.
- Conditions
- Schizophrenia Cognition Autobiographical Memory Cognitive Remediation, SCHIZOPHRENIA 1 (Disorder), Hospitalized Adult Patients
- Trial name
- NCT07512843
- Testing
- Group reminiscence therapy
- Where
- Jordan
- Volunteers
- 38 people
- Sponsor
- The Hashemite University
Bipolar Disorder, Schizophrenia
Trial to Assess the Bioavailability of Quetiapine Versus Seroquel® in Subjects With Schizophrenia or Bipolar Disorder
This is a two-part trial. The primary objective of Part A is to estimate the ratio of geometric means of pharmacokinetic (PK) parameters and their within-subject variability for the 300mg quetiapine tablet formulation A and the…
- Trial name
- NCT03872596
- Testing
- Seroquel IR 300mg, Seroquel IR 25mg, Quetiapine Formulation A 300mg
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Cognition, Functioning and Quality of Life
People affected by schizophrenia often experience poor concentration, lapses in memory and difficulty with completing tasks; and this set of problems are known as neuro-cognitive deficits.
- Trial name
- NCT00182442
- Testing
- Olanzapine & Quetiapine
- Where
- Canada
- Volunteers
- 80 people
- Sponsor
- Hamilton Health Sciences Corporation
Tobacco Use Cessation, Tobacco Use Disorder
Treating Nicotine Dependence in Schizophrenic Individuals: Effectiveness of Bupropion - 1
Schizophrenic individuals are typically nicotine dependent smokers who find it difficult to quit smoking. The purpose of this study is to determine the effectiveness of bupropion SR (commonly known as Zyban) in combination with a…
- Conditions
- Tobacco Use Cessation, Tobacco Use Disorder, Schizophrenia
- Trial name
- NCT00124683
- Testing
- Bupropion, nicotine transdermal patch
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Schizophrenia; Psychosis, Schizophrenia and Related Disorders
Accelerated rTMS for Psychomotor Slowing
The goal of this clinical trial is to optimize the treatment of psychomotor slowing in patients with schizophrenia using Transcranial Magnetic Stimulation (TMS).
- Conditions
- Schizophrenia; Psychosis, Schizophrenia and Related Disorders, Schizo Affective Disorder, Brief Psychotic Disorder
- Trial name
- ATMSSlowing (NCT06134661)
- Testing
- cTBS (continuous Theta Burst Stimulation)
- Where
- Switzerland
- Volunteers
- 25 people
- Sponsor
- University of Bern
Tobacco Dependence, Schizophrenia
The Pharmacogenetic Study , Readiness to Change, and Pharmacological Intervention for Smoking Cessation in Schizophrenia
Cigarette smoking represents a major health problem for patients suffering from schizophrenia. Compared to the general population, schizophrenic patients are significantly more likely to be addicted to nicotine.
- Trial name
- PSIAARP (NCT00495352)
- Testing
- Hihg-doseNRT, Low-dose NRT, bupropion
- Where
- Taiwan
- Volunteers
- 360 people
- Sponsor
- Yu-Li Hospital
Schizophrenia
Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With Schizophrenia
To determine the pharmacokinetics, safety and tolerability of brexpiprazole administered subcutaneously or intramuscularly in adults with schizophrenia.
- Trial name
- NCT02968121
- Testing
- Brexpiprazole, OPDC-34712
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Cognitive Function 1, Social
Social Cognition Assessment in Young Adults
The primary objective of this study is to determine the efficacy and feasibility of a battery of neuropsychological measures evaluating social cognition and behavior in young adults diagnosed with schizophrenia, autism spectrum…
- Trial name
- NCT02922400
- Testing
- Social Cognition Assessment and Training
- Where
- United States
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- The University of Texas at Dallas
SCHIZOPHRENIA 1 (Disorder), Schizoaffective Disorder
Cognitive Neurocomputational Task Reliability & Clinical Applications Consortium (CNTRACS): Study 1
In Study 1, investigators will test the ability of each of the seven paradigms to differentiate between schizophrenia (SZ)/schizoaffective disorder (SZA) and matched healthy control subjects (HC) and to predict individual…
- Conditions
- SCHIZOPHRENIA 1 (Disorder), Schizoaffective Disorder, Healthy Adult Participants
- Trial name
- CNTRACS (NCT07853807)
- Testing
- Motion Perception Task, Sine Wave Speech Task, Volatility Task
- Where
- 5 sites in United States
- Volunteers
- 325 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Schizophrenia
A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia
The purpose of this study is to evaluate the safety and tolerability of multiple ascending oral doses of ASP4345 in patients with schizophrenia.
- Trial name
- NCT02720263
- Testing
- ASP4345
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Schizophrenia, Psychoses
Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
Prodrome based early intervention with an antipsychotic drug vs. benzodiazepine was applied in patients with first episode schizophrenia after one year neuroleptic maintenance treatment.
- Trial name
- NCT00159133
- Testing
- antipsychotics vs. Lorazepam (Drugs)
- Where
- Germany
- Volunteers
- 71 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Schizophrenia, Cerebellar Ataxia
A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants
The purpose of this study is to determine the safety, tolerability and pharmacokinetics (PK) of single and multiple rising doses of TAK-831 in healthy participants.
- Trial name
- NCT02566759
- Testing
- TAK-831 Oral Suspension, TAK-831 Tablet
- Where
- United Kingdom
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Neurocrine Biosciences
Healthy
Study Of The PF-04958242 Blood Concentrations Of A Capsule Formulation Of PF-04958242 Compared To A Solution Formulation
This study will assess the relative bioavailability of a capsule formulation of PF-04958242, relative to a oral solution formulation of PF-04958242 in healthy adult subjects.
- Trial name
- NCT01646840
- Testing
- PF-04958242 capsule, PF-04958242 oral solution
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Biogen
Schizophrenia
Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia in 2 Parts (Part 1 and 2).
This is a multiple oral dose, open-label study to assess the safety, tolerability, and pharmacokinetics of SEP-363856 in Japanese subjects with schizophrenia.
- Trial name
- NCT03370640
- Testing
- SEP-363856
- Where
- 8 sites in Japan
- Volunteers
- 24 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Schizophrenia, Psychotic Disorders
Investigation of the Drug Dimethoxbenzylidene Anabaseine in Treating Schizophrenia Patients
This study will determine the effectiveness of a drug, dimethoxbenzylidene anabaseine, in producing beneficial effects similar to that of nicotine in individuals with schizophrenia.
- Trial name
- NCT00255918
- Testing
- Dimethoxybenzylidene anabaseine (DMXB-A)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Colorado, Denver
Healthy Participants, Schizophrenia Diagnosis
Single and Multiple Ascending Doses of NTX-253 in Healthy Participants and Participants With Stable Schizophrenia
This study will assess the safety, tolerability, and pharmacokinetics of NTX-253 following oral administration in both healthy adult participants as well as adult participants with stable schizophrenia.
- Trial name
- NCT07344948
- Testing
- NTX-253
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Neurosterix
Schizophrenia, Alzheimer's Disease Psychosis
A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020
This is a randomized, double-blind, placebo-controlled, ascending multiple oral dose study to assess the safety, tolerability, and pharmacokinetics of LY03020 in Chinese healthy adult subjects and/or subjects with stable…
- Trial name
- NCT07230652
- Testing
- LY03020
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Alzheimer's Disease Psychosis, Parkinson Disease Psychosis
Effect of Food and Age on the Pharmacokinetics of LY03017
This study consists of 2 parts. Part A is a randomized, open-label, 2-period, crossover study to evaluate the food effect of LY03017 in healthy adults.
- Conditions
- Alzheimer's Disease Psychosis, Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia
- Trial name
- NCT06793995
- Testing
- LY03017
- Where
- China
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.